⌘K
Loading ticker…
As of 2026-08-24, Lipocine Inc. (LPCN) has a 3-month relative strength percentile of 32 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.3%, relative volume 0.65×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
LPCN is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -8.2% / -54.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
LPCN is held by 2 ETFs as of Apr 2026. Top owner: DFAS at 0.00% weight, $14K notional.
Held by 4 ETFs · $2M across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFASDimensional U.S. Small Cap ETF | 0.00% | $14K | new |
| DFACDimensional U.S. Core Equity 2 ETF | 0.00% | $11K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LPCN Jan avg: 18.41% median: 22.66% win: 75% σ: 23.16% n: 4 2022-04-12 → 2026-07-31 | LPCN Feb avg: -8.86% median: -8.58% win: 25% σ: 16.96% n: 4 2022-04-12 → 2026-07-31 | LPCN Mar avg: -2.31% median: -8.10% win: 50% σ: 29.35% n: 4 2022-04-12 → 2026-07-31 | LPCN Apr avg: -24.03% median: -18.27% win: 20% σ: 28.20% n: 5 2022-04-12 → 2026-07-31 | LPCN May avg: 9.04% median: 2.11% win: 60% σ: 23.31% n: 5 2022-04-12 → 2026-07-31 | LPCN Jun avg: 6.79% median: 8.86% win: 60% σ: 10.55% n: 5 2022-04-12 → 2026-07-31 | LPCN Jul avg: -11.81% median: -5.93% win: 20% σ: 15.75% n: 5 2022-04-12 → 2026-07-31 | LPCN Aug avg: -20.75% median: -21.77% win: 0% σ: 8.17% n: 4 2022-04-12 → 2026-07-31 (current) | LPCN Sep avg: -6.67% median: -12.24% win: 25% σ: 21.84% n: 4 2022-04-12 → 2026-07-31 | LPCN Oct avg: -1.71% median: -7.89% win: 25% σ: 17.04% n: 4 2022-04-12 → 2026-07-31 | LPCN Nov avg: 3.96% median: 2.28% win: 50% σ: 20.45% n: 4 2022-04-12 → 2026-07-31 | LPCN Dec avg: 36.27% median: 11.63% win: 75% σ: 65.78% n: 4 2022-04-12 → 2026-07-31 |